BiotechTube
EndoClot Plus

EndoClot Plus

San Jose, United States· Est.
endoclot.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

EndoClot Plus is a medical device innovator specializing in hemostasis and therapeutic solutions for GI bleeding. Its core technology is the EndoClot PHS, a polysaccharide-based powder delivery system designed for rapid, topical bleeding control during endoscopy. The company has established commercial manufacturing in China and is pursuing regulatory approvals to expand globally, though its products are not yet cleared for the U.S. market. Its mission is to become a leader in novel biomaterial devices for GI endoscopy by leveraging clinical and material science expertise.

Gastrointestinal Bleeding

Technology Platform

Proprietary absorbable polysaccharide powder platform for topical hemostasis and tissue sealing/spacing. The platform includes specialized delivery systems for endoscopic application.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

Large and growing global market for GI endoscopic devices, driven by aging demographics and increased cancer screening.
The proprietary, non-thermal hemostasis technology addresses limitations of current standard-of-care tools.
Manufacturing base in China provides cost advantages and direct access to the high-growth Asian healthcare market.

Risk Factors

Failure to obtain U.S.
FDA clearance blocks access to the largest single market.
Faces intense competition from large, established medical device companies with extensive sales forces and bundled product offerings.
Operational complexity of managing a U.S.-China corporate and manufacturing structure.

Competitive Landscape

Competes in the GI hemostasis segment against dominant players like Olympus, Boston Scientific, and Cook Medical, who offer mechanical clips, thermal probes, and injection needles. Also competes with other hemostatic powders/sprays (e.g., Hemospray). Differentiation is based on EndoClot's specific polysaccharide formulation, delivery mechanism, and its expansion into adjunctive products like submucosal injection fluid.

More companies in Digital Health & Biotech SaaS →More companies in United States →